Johnson and Johnson announces acceleration in vaccine development

Published Jun 11, 2020


CAPE TOWN - Johnson and Johnson have released a media statement discussing their Covid-19 vaccine development and how their efforts will be accelerated with human testing soon to take place.

The global fight of Covid-19 heavily relies on a vaccine to be produced urgently as many countries are yet to hit their peaks with 7,15 million confirmed cases throughout the world.

The company announced that human trials will begin sooner than initially planned. Rather than scheduled tests to take place in September, the first phases of human trials are expected to begin at the end of July.

“Based on the strength of the preclinical data we have seen so far and interactions with the regulatory authorities, we have been able to further accelerate the clinical development of our investigational SARS-CoV-2 vaccine,” said Paul Stoffels, M.D., the Vice Chairman of the Executive Committee and Chief Scientific Officer, Johnson & Johnson.

“Simultaneously, we are continuing our efforts to build important global partnerships and invest in our vaccine production technology and manufacturing capabilities. Our goal is to ensure we can deliver a vaccine to the world and protect people everywhere from this pandemic.”

The study will take place in the US and Belgium, testing 1045 healthy adults aged 18 to 55 years as well as adults 65 years and older.

According to the statement the company committed to a goal to provide more than 1 billion vaccine doses throughout the world and while the vaccine development progresses, the company is also looking at ways to expand manufacturing capacity and worldwide access with their global partners.

For LIVE updates on the Coronavirus pandemic, follow us on Twitter: @sacoronamonitor


Related Topics:

covid 19